Stock Events

Stock Events

Immix Biopharma 

$9.11
0
+$1.09+13.59% Today

Statistics

Day High
9.11
Day Low
8.02
52W High
-
52W Low
-
Volume
201
Avg. Volume
-
Mkt Cap
305.9M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q3 2025
Q4 2025
Next
-0.27
-0.23
-0.19
-0.15
Expected EPS
-0.2075
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-43.23MNet Income

Analyst Ratings

$18.00Average Price Target
The highest estimate is 23.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
75%
Hold
25%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMMX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, directly competing in the biopharma space.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for the treatment of serious diseases, overlapping with Immix's therapeutic areas.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, competing in the same innovative drug development space as Immix.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation specializes in the discovery, development, and commercialization of proprietary therapeutics, directly competing with Immix in the oncology and inflammation markets.
Exelixis
EXEL
Mkt Cap10.41B
Exelixis, Inc. is a biotechnology company that develops and sells small molecule therapies for the treatment of cancer, competing in the oncology space with Immix.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, a large pharmaceutical company, competes across a broad range of therapeutic areas, including those targeted by Immix Biopharma.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, directly competing with Immix.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is one of the world's leading biotechnology companies, focusing on areas such as oncology/hematology, cardiovascular disease, and more, competing across several therapeutic areas with Immix.

About

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Show more...
CEO
ISIN
US45258H1068

Listings

XNAS
US
IMMX
BOATS
BOATS
IMMX.BOATS

0 Comments

Share your thoughts

FAQ

What is Immix Biopharma stock price today?▼
The current price of IMMX.BOATS is $9.11 USD — it has increased by +13.59% in the past 24 hours. Watch Immix Biopharma stock price performance more closely on the chart.
What is Immix Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Immix Biopharma stocks are traded under the ticker IMMX.BOATS.
What is Immix Biopharma market cap?▼
Today Immix Biopharma has the market capitalization of 305.9M
When is the next Immix Biopharma earnings date?▼
Immix Biopharma is going to release the next earnings report on June 03, 2026.
What were Immix Biopharma earnings last quarter?▼
IMMX.BOATS earnings for the last quarter are -0.27 USD per share, whereas the estimation was -0.15 USD resulting in a -86.21% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Immix Biopharma revenue for the last year?▼
Immix Biopharma revenue for the last year amounts to 0 USD.
What is Immix Biopharma net income for the last year?▼
IMMX.BOATS net income for the last year is -43.23M USD.
When did Immix Biopharma complete a stock split?▼
Immix Biopharma has not had any recent stock splits.